Syndax Pharmaceuticals Inc (SNDX) - Net Assets
Based on the latest financial reports, Syndax Pharmaceuticals Inc (SNDX) has net assets worth $115.43 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($551.79 Million) and total liabilities ($436.36 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check SNDX asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $115.43 Million |
| % of Total Assets | 20.92% |
| Annual Growth Rate | N/A |
| 5-Year Change | 14.25% |
| 10-Year Change | 331.98% |
| Growth Volatility | 221.41 |
Syndax Pharmaceuticals Inc - Net Assets Trend (2011–2024)
This chart illustrates how Syndax Pharmaceuticals Inc's net assets have evolved over time, based on quarterly financial data. Also explore SNDX asset base for the complete picture of this company's asset base.
Annual Net Assets for Syndax Pharmaceuticals Inc (2011–2024)
The table below shows the annual net assets of Syndax Pharmaceuticals Inc from 2011 to 2024. For live valuation and market cap data, see SNDX market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $288.12 Million | -48.01% |
| 2023-12-31 | $554.20 Million | +18.56% |
| 2022-12-31 | $467.45 Million | +14.47% |
| 2021-12-31 | $408.37 Million | +61.93% |
| 2020-12-31 | $252.19 Million | +698.06% |
| 2019-12-31 | $31.60 Million | -40.43% |
| 2018-12-31 | $53.05 Million | -49.15% |
| 2017-12-31 | $104.32 Million | +23.98% |
| 2016-12-31 | $84.14 Million | +26.15% |
| 2015-12-31 | $66.70 Million | +1266.86% |
| 2014-12-31 | $-5.72 Million | -148.24% |
| 2013-12-31 | $11.85 Million | +140.46% |
| 2012-12-31 | $-29.29 Million | -53.70% |
| 2011-12-31 | $-19.05 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Syndax Pharmaceuticals Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 115225800000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $9.00K | 0.00% |
| Other Comprehensive Income | $163.00K | 0.06% |
| Other Components | $1.51 Billion | 523.77% |
| Total Equity | $288.12 Million | 100.00% |
Syndax Pharmaceuticals Inc Competitors by Market Cap
The table below lists competitors of Syndax Pharmaceuticals Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
TX Group AG
SW:TXGN
|
$1.66 Billion |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
$1.66 Billion |
|
Medicover AB (publ)
ST:MCOV-B
|
$1.66 Billion |
|
Dis-Chem Pharmacies
JSE:DCP
|
$1.66 Billion |
|
Guangdong Yizumi Precision Machinery Co Ltd
SHE:300415
|
$1.66 Billion |
|
SJM HOLDINGS UNSP.ADR/4
F:3MG1
|
$1.66 Billion |
|
Attendo AB (publ)
ST:ATT
|
$1.66 Billion |
|
Airport City Ltd
TA:ARPT
|
$1.66 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Syndax Pharmaceuticals Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 554,196,000 to 288,124,000, a change of -266,072,000 (-48.0%).
- Net loss of 318,758,000 reduced equity.
- Other comprehensive income decreased equity by 55,000.
- Other factors increased equity by 52,741,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-318.76 Million | -110.63% |
| Other Comprehensive Income | $-55.00K | -0.02% |
| Other Changes | $52.74 Million | +18.3% |
| Total Change | $- | -48.01% |
Book Value vs Market Value Analysis
This analysis compares Syndax Pharmaceuticals Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 5.68x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-12-31 | $0.00 | $19.11 | x |
| 2012-12-31 | $-0.42 | $19.11 | x |
| 2013-12-31 | $1.48 | $19.11 | x |
| 2014-12-31 | $-0.60 | $19.11 | x |
| 2015-12-31 | $11.93 | $19.11 | x |
| 2016-12-31 | $5.76 | $19.11 | x |
| 2017-12-31 | $4.97 | $19.11 | x |
| 2018-12-31 | $2.09 | $19.11 | x |
| 2019-12-31 | $1.04 | $19.11 | x |
| 2020-12-31 | $6.11 | $19.11 | x |
| 2021-12-31 | $7.84 | $19.11 | x |
| 2022-12-31 | $7.69 | $19.11 | x |
| 2023-12-31 | $7.88 | $19.11 | x |
| 2024-12-31 | $3.37 | $19.11 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Syndax Pharmaceuticals Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -110.63%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1346.11%
- • Asset Turnover: 0.03x
- • Equity Multiplier: 2.52x
- Recent ROE (-110.63%) is below the historical average (-56.10%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 0.00% | 0.00% | 0.00x | 0.00x | $-11.18 Million |
| 2012 | 0.00% | 0.00% | 0.00x | 0.00x | $-7.04 Million |
| 2013 | -119.60% | 0.00% | 0.00x | 1.44x | $-15.36 Million |
| 2014 | 0.00% | 0.00% | 0.00x | 0.00x | $-19.26 Million |
| 2015 | -36.16% | -3846.73% | 0.01x | 1.35x | $-30.79 Million |
| 2016 | -52.86% | -3645.25% | 0.01x | 1.30x | $-52.89 Million |
| 2017 | -58.28% | -2884.35% | 0.02x | 1.32x | $-71.23 Million |
| 2018 | -139.43% | -4875.48% | 0.02x | 1.58x | $-79.27 Million |
| 2019 | -177.07% | -3688.53% | 0.02x | 2.01x | $-59.12 Million |
| 2020 | -28.97% | -4816.68% | 0.01x | 1.19x | $-98.29 Million |
| 2021 | 6.10% | 17.84% | 0.31x | 1.10x | $-15.91 Million |
| 2022 | -30.75% | -113.57% | 0.25x | 1.06x | $-190.49 Million |
| 2023 | -37.78% | 0.00% | 0.00x | 1.11x | $-264.78 Million |
| 2024 | -110.63% | -1346.11% | 0.03x | 2.52x | $-347.57 Million |
Industry Comparison
This section compares Syndax Pharmaceuticals Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Syndax Pharmaceuticals Inc (SNDX) | $115.43 Million | 0.00% | 3.78x | $1.66 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About Syndax Pharmaceuticals Inc
Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory (R/R) acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. … Read more